• Link to LinkedIn
  • Link to X
  • Link to Facebook
  • Contact Us
  • Careers
Spermosens AB
  • Technology
    • IP Status
    • White Paper
  • Team
    • Core Team
    • Board
    • Partners
  • About us
    • Milestones
    • Sustainable Development Goals
    • Sponsorships & Memberships
    • Advisory Board Members
  • Investors
    • TO 6
    • The Share
    • Financial Calendar
    • Press & Media
    • Financial Reports
    • Board
    • Corporate Governance
  • Press & Media
    • Press Releases
    • Presentations
    • Interviews
    • Articles
    • Photos & Logo
  • ART Academy
  • Menu Menu

Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026

The session is organised as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The webcast follows the publication of the Company's Q1 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the publication of each quarterly report.

Webcast Details

  • Date: Tuesday, 19 May 2026
  • Time: 12:00 CET
  • Language: English and Swedish
  • Access Link: https://teams.microsoft.com/meet/357257725442193?p=EqSPcplBz6BK22HKXe

 

Meeting ID: 357 257 725 442 193

Passcode: rs2hA9A4

 

Participation and Submission of Questions

The webcast is open to all interested parties. Participants are invited to submit questions in advance to ensure a focused and productive session. The Company may consolidate similar queries to address as many topics as possible during the live webcast.

  • Advance Questions: Please email info@spermosens.com
  • Deadline for Submission: Monday, 18 May 2026

 

 

About Spermosens AB

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specialises in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market.

The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com.

 

 

Attachments

  • 📎 Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026 PDF
← Back to press releases
11 May, 2026
Share this entry
  • Share on X
  • Share on LinkedIn
  • Share by Mail
https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png 0 0 https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png 2026-05-11 13:59:072026-11-14 21:54:29Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026

Press releases

  • 12 November, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT JULY – SEPTEMBER 2026 Our focus is shifting from development to go-to-market preparations   1 JULY – 30… Read more
  • 9 November, 2026 Regulatory Leading Australian fertility group Genea to run first independent clinical study of JUNO-Checked Spermosens AB has signed a collaboration framework agreement with Genea Pty Ltd (Genea), one of… Read more
  • 20 October, 2026 Spermosens presents JUNO-Checked at ASRM 2026 in Baltimore Spermosens AB (publ) (“Spermosens” or the “Company”) announces that the Company has been admitted to the … Read more
  • 1 September, 2026 Regulatory Bulletin from Extraordinary General Meeting in Spermosens AB (publ) Today, September 1, 2026, the Extraordinary General Meeting was held. Below is a summary of the… Read more
  • 21 August, 2026 Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026 Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live… Read more
  • 20 August, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026 In the second quarter of 2026, we saw recruitment into its Generation 3 clinical validation study… Read more

Spermosens AB

MEDICON VILLAGE
Scheeletorget 1
223 81 Lund, Sweden

 

  • Quality & Regulatory
  • Privacy Policy
Cookie settings
© Copyright 2025 - Spermosens AB | Photos from Unsplash.com | Icons from Flaticon.com | Website by 8612 Hemsidesproduktion
  • Link to LinkedIn
  • Link to X
  • Link to Facebook
Link to: Spermosens secures SEK 4.85 million capital facility to support development and commercialization Link to: Spermosens secures SEK 4.85 million capital facility to support development and commercialization Spermosens secures SEK 4.85 million capital facility to support development... Link to: KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ) Link to: KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ) KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)
Scroll to top Scroll to top Scroll to top

This site uses cookies. Please accept the settings or adjust them to your personal preference.

Accept settingsHide this notificationSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide the notification